Integrin alpha V beta 6

Integrin alpha V beta 6

Integrin alpha V beta 6 Overview

Molecule Name
Integrin alpha-V/beta-6
Drug Development Progress
Drugs in Clinical Trials6
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
Background
Integrin alpha V beta 6 is a heterodimer of beta-6 associating with alpha-V. Integrin alpha-V beta-6 is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. Internalisation of integrin alpha-V beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion. Also, Integrin alpha-V beta-6 acts as a receptor for coxsackievirus A9 and coxsackievirus B1 as well as herpes simplex virus-1/HHV-1. Furthermore, it binds the TGF-beta latency‑associated peptide (LAP) and activates TGF-beta 1 or TGF-beta 3 from large latent complexes. This activation requires interaction with LTBP-1 and fibronectin, and is enhanced by PAR-1.

Integrin alpha V beta 6 Product List

Species
  • Cynomolgus(2)
  • Human(2)
  • Mouse(2)
  • Mouse & Human(1)
  • Rat(1)
Tag
  • His Tag(5)
  • His Tag & Avi Tag(3)
Host
  • HEK293(8)
Conjugate
  • Unconjugated(5)
  • Biotin-labeled(3)
Grade
  • RUO(8)
Low Endotoxin
  • Yes(3)
  • No(5)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
Integrin alpha V beta 6
Human Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein, His Tag&Tag Free, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPR

$485.00

100ug
Integrin alpha V beta 6
Mouse Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein, His Tag&Tag Free (MALS verified)
Mouse
HEK293
MALSSDS-PAGE
ELISABLI

$485.00

100ug
Integrin alpha V beta 6
Cynomolgus Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein, His Tag&Tag Free, low endotoxin (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISASPR

$485.00

100ug
Integrin alpha V beta 6
HOTAvitag
IT6-H82E4
Biotinylated Human Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein, His,Avitag™&Tag Free (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$435.00

25ug
Integrin alpha V beta 6
Avitag
IT6-C82E3
Biotinylated Cynomolgus Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein, His,Avitag™&Tag Free
Cynomolgus
HEK293
SDS-PAGE
ELISA

$360.00

25ug
Integrin alpha V beta 6
Mouse & Human Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein, His Tag&Tag Free, low endotoxin (MALS verified)
Mouse & Human
HEK293
MALSSDS-PAGE
ELISA

$485.00

100ug
Integrin alpha V beta 6
Avitag
IT6-M82W9
Biotinylated Mouse Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein, His,Avitag™&Tag Free (MALS verified)
Mouse
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
Integrin alpha V beta 6
Rat Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein, His Tag&Tag Free (MALS verified)
Rat
HEK293
MALSSDS-PAGE
ELISA

$420.00

100ug
You Have Viewed 1-8 Of 8 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

FAQ

How should αVβ6 cross-species binding be assessed before animal studies?

Screen against human αVβ6, then compare the homolog from the intended model, such as cynomolgus, mouse, or rat. Use matched heterodimer formats and assay conditions to avoid construct-driven differences.

When should recombinant αVβ6 protein and an αVβ6 stable cell line be used together?

Recombinant αVβ6 supports controlled affinity and biochemical inhibition assays. A stable cell line then confirms recognition of membrane-displayed αVβ6 and reveals accessibility or avidity effects.

Why is a MALS-verified αVβ6 heterodimer important for inhibitor screening?

The binding surface depends on the assembled αV and β6 subunits. SEC-MALS helps confirm the expected molecular assembly and detect aggregation that could distort multivalent binding signals.

How should RGD-ligand and divalent-cation conditions be controlled in αVβ6 assays?

αVβ6 recognition is RGD- and conformation-dependent, and Ca²⁺, Mg²⁺, or Mn²⁺ can alter apparent affinity. Keep ligand source, cation composition, and chelator content constant across candidates and lots.

How can direct αVβ6 blockade be distinguished from downstream TGF-β pathway inhibition?

Measure disruption of the αVβ6–latent TGF-β1 interaction first, using a binding assay such as TR-FRET. Follow with a cell-based TGF-β readout to determine whether pathway inhibition is consistent with direct target blockade.
Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
IDL-2965IDL-2965Phase 2 ClinicalIndalo Therapeutics Inc
Idiopathic Pulmonary Fibrosis; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
BexotegrastPLN-74809Phase 2 ClinicalPliant Therapeutics Inc
Cholangitis, Sclerosing; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Respiratory Distress Syndrome, Adult
Details
NesvategrastSF-0166; OTT-166(OcuTerra Therapeutics)Phase 2 ClinicalOcuTerra Therapeutics Inc, Scifluor Life Sciences Inc
Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration
Details
18F-αvβ6-Binding-Peptide18F-αvβ6-BPPhase 1 ClinicalNational Cancer Institute, National Institutes Of Health
Breast Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Lung Neoplasms; Metastatic breast cancer; Pancreatic Neoplasms; Rectal Neoplasms
Details
[18F]FP-R01-MG[18F]FP-R01-MG-F2; [18F]FP-R01-MGPhase 1 ClinicalChinese Academy Of Medical Science & Peking Union Medical College, Pliant Therapeutics Inc, Stanford University
Brain metastases; Carcinoma, Non-Small-Cell Lung; Cholangitis, Sclerosing; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Pancreatic Neoplasms
Details
Ga-68-TrivehexinRAD-301Phase 1 ClinicalTrimt GmbH
Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Ovarian Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms
Details
Customer Reviews